M2-型丙酮酸激酶(PKM2)重組蛋白
Recombinant Pyruvate kinase isozymes M2 (PKM2)
M2PK; PKM; M2-PK; PKM1; CTHBP; OIP3; PK3; PKM; TCB; THBP1; Pyruvate kinase muscle isozyme; Thyroid hormone-binding protein 1; Cytosolic thyroid hormone-binding protein; Pyruvate Kinase, Muscle
- 編號(hào)URPA588Hu03
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測(cè)定)
- 亞細(xì)胞定位細(xì)胞核, 細(xì)胞質(zhì)
- 預(yù)測(cè)分子量87.9kDa
- 實(shí)際分子量88kDa(差異分析請(qǐng)參閱說明書)
- 片段與標(biāo)簽Met1~Pro531 with N-terminal His and GST Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 95%
- 等電點(diǎn)7.9
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請(qǐng)參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 564 ¥ 1410 ¥ 2820 ¥ 8460 ¥ 21150
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月，-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA588Hu01 | M2-型丙酮酸激酶(PKM2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA588Hu02 | M2-型丙酮酸激酶(PKM2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA588Hu03 | M2-型丙酮酸激酶(PKM2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA588Hu02 | M2-型丙酮酸激酶(PKM2)活性蛋白 | Cell?culture;?Activity?Assays. |
| UPAA588Hu02 | M2-型丙酮酸激酶(PKM2)多克隆抗體 | WB; IHC; ICC/IF; FCM |
| UPAA588Hu03 | M2-型丙酮酸激酶(PKM2)多克隆抗體 | WB; IHC; ICC/IF |
| UPAA588Hu01 | M2-型丙酮酸激酶(PKM2)多克隆抗體 | WB; IHC; ICC/IF; FCM |
| UFAA588Hu01 | 抗M2-型丙酮酸激酶(PKM2)多克隆抗體 | FCM |
| UFAA588Hu03 | 抗M2-型丙酮酸激酶(PKM2)多克隆抗體 | FCM |
| UMAA588Hu24 | M2-型丙酮酸激酶(PKM2)單克隆抗體 | WB |
| UMAA588Hu22 | M2-型丙酮酸激酶(PKM2)單克隆抗體 | WB |
| UMAA588Hu23 | M2-型丙酮酸激酶(PKM2)單克隆抗體 | WB; ICC/IF |
| UMAA588Hu21 | M2-型丙酮酸激酶(PKM2)單克隆抗體 | WB |
| USEA588Hu | M2-型丙酮酸激酶(PKM2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA588Hu | M2-型丙酮酸激酶(PKM2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Cancer Research | Antigen Presentation by Dendritic Cells in Tumors Is Disrupted by Altered Metabolism that Involves Pyruvate Kinase M2 and Its Interaction with SOCS3 [AACR: 70189] |
| Molecular BioSystems | Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer [Pubmed:25483567] |
| Tumour Biol | M2 isoform of pyruvate kinase (PKM2) is upregulated in Kazakh’s ESCC and promotes proliferation and migration of ESCC cells [PubMed: 26404132] |
| Oncotarget | Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis [Pubmed:29707118] |
| Journal of?Neurotrauma | Acteoside improves muscle atrophy and motor function by inducing new myokine secretion in chronic spinal cord injury [Pubmed: 30318996] |
| Cell Reports | Secreted Pyruvate Kinase M2 Promotes Lung Cancer Metastasis through Activating the Integrin Beta1/FAK Signaling Pathway [Pubmed: 32049010] |
| Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC) [] | |
| Cancer Cell International | Bufalin Induced Mitochondrial Dysfunction Promotes Apoptosis of Glioma Cells by Regulating Annexin A2 and DRP1 Proteins [] |
| Cancer Cell Int | Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression [34376212] |
| Life (Basel) | Putative Association between Low Baseline Gene Expression in the Peripheral Blood and Clinical Remission in Rheumatoid Arthritis Patients Treated with Tofacitinib [34947916] |
留言咨詢
